PLoS ONE (Jan 2013)

Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer.

  • Qinchuan Wang,
  • Xiyong Liu,
  • Jichun Zhou,
  • Yasheng Huang,
  • Shengjie Zhang,
  • Jianguo Shen,
  • Sofia Loera,
  • Xiaoming Yuan,
  • Wenjun Chen,
  • Mei Jin,
  • Stephen Shibata,
  • Yingbin Liu,
  • Peiguo Chu,
  • Linbo Wang,
  • Yun Yen

DOI
https://doi.org/10.1371/journal.pone.0070191
Journal volume & issue
Vol. 8, no. 7
p. e70191

Abstract

Read online

ObjectivesWe aimed to investigate the prognostic value of RRM1 in GC patients.MethodsA total of assessable 389 GC patients with clinicopathological and survival information were enrolled from City of Hope (COH, n = 67) and Zhejiang University (ZJU, n = 322). RRM1 protein expression was determined by immunohistochemistry on FFPE tissue samples. Kaplan-Meier and Cox analyses were used to measure survival. Ras/Raf activity and invasion assays were used to evaluate the role of RRM1 in GC cell lines.ResultsIn vitro experiments demonstrated RRM1 activated Ras/Raf/MAPK signal transduction and promoted GC cell proliferation. Meanwhile, RRM1 expression was significantly associated with lymph node involvement, tumor size, Ki67 expression, histological subtype and histological grade in the GC tissue samples (pConclusionsRRM1 overexpression predicts poor survival in GC patients with advanced TNM stage. RRM1 could potentially serve as prognostic biomarker and therapeutic target for GCs.